HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Nebido in the treatment of hypogonadism syndrome and its complications in men].

Abstract
The article presents original experience with use of undecanoate (nebido, BayerHealthcare Pharmaceuticals, Germany) in androgenic testosteron replacement therapy in males with hypogonadism. Prospective studies of nebido efficacy were made in males with vein-occlusive erectile dysfunction (n = 20), chronic pelvic pain syndrome (n = 77), metabolic syndrome (n = 170). Retrospective studies assessed efficacy of nebido monotherapy in patients with erectile dysfunction and hypogonadism (n = 34), hematological and urological safety of the drug (n = 40). Laboratory monitoring was performed in all the studies according to ISSAM recommendations. The patients were not included in contraindications to androgenic therapy. Nebido treatment significantly improved libido and erectile function, efficacy of phosphodiesterase of type 5 inhibiors used in moderate and severe erectile dysfunction. Depressive, asthenic, pain symptoms declined in males with chronic pelvic pain. Body fat reduced in metabolic syndrome with alleviation of its other components. Insignificant rise of hemoglobin level and packed cell volume was observed in some patients while a PSA level increase was clinically significant in 10% patients who had initial PSA > 2.5 ng/ml and acromegalia. Also, nebido depressed production of gonadotropins and spermatogenesis. Thus, nebido is highly effective in sexual dysfunction and other somatic disorders caused by hypogonadism. Nebido does not induce severe side effects, but clinically significant rise of PSA level requires treatment discontinuation and more careful urological examination. In view of nebido ability to suppress spermatogenesis, the drug should not be used in reproductively active men.
AuthorsI I Dedov, D G Kurbatov, R V Rozhivanov, A E Lepetukhin, S A Dubskiĭ, N P Goncharov
JournalUrologiia (Moscow, Russia : 1999) (Urologiia) 2011 Nov-Dec Issue 6 Pg. 59-60, 62-7 ISSN: 1728-2985 [Print] Russia (Federation)
PMID22448484 (Publication Type: Journal Article)
Chemical References
  • Androgens
  • Phosphodiesterase 5 Inhibitors
  • Testosterone
  • testosterone undecanoate
Topics
  • Adult
  • Aged
  • Androgens (adverse effects, therapeutic use)
  • Hormone Replacement Therapy
  • Humans
  • Hypogonadism (complications, drug therapy, pathology, physiopathology)
  • Impotence, Vasculogenic (complications, drug therapy, pathology, physiopathology)
  • Libido (drug effects)
  • Male
  • Metabolic Syndrome (complications, drug therapy, pathology, physiopathology)
  • Middle Aged
  • Pelvic Pain (complications, drug therapy, pathology, physiopathology)
  • Penile Erection (drug effects)
  • Phosphodiesterase 5 Inhibitors (administration & dosage, adverse effects)
  • Prospective Studies
  • Retrospective Studies
  • Spermatogenesis (drug effects)
  • Syndrome
  • Testosterone (adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: